Related Experiment Video
Updated: Jul 19, 2026
12:24
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Now, later or never? Challenges associated with hepatitis C treatment
S McNally1, M Temple-Smith, W Sievert
1Australian Research Centre in Sex, Health and Society, La Trobe University, Victoria. s.mcnally@latrobe.edu.au
Australian and New Zealand Journal of Public Health
|November 1, 2006
Summary
Many Australians with hepatitis C virus (HCV) face barriers to starting and adhering to antiviral therapy. Treatment effectiveness influences decisions, while side effects pose the biggest adherence challenge.
Area of Science:
- Hepatology
- Infectious Diseases
- Public Health
Background:
- Hepatitis C virus (HCV) infection affects an estimated 259,000 Australians.
- Antiviral therapy uptake remains low despite available treatments.
Purpose of the Study:
- To identify barriers to initiating hepatitis C virus (HCV) antiviral therapy.
- To explore challenges in adhering to HCV treatment regimens.
Main Methods:
- A survey was administered to 224 hepatitis C antibody-positive individuals in Victoria.
- Participants included those currently on, previously on, or never treated for HCV.
Main Results:
- Treatment effectiveness was the primary factor influencing the decision to start therapy.
- Side effects were the main challenge to treatment adherence and a key reason for not starting treatment.
- Men and those diagnosed more recently were more likely to be receiving treatment.
Conclusions:
- Treatment decisions and adherence are influenced by multiple factors.
- Promoting information on new, effective treatments can increase uptake.
- Effective side effect management is crucial for improving HCV treatment adherence.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:28Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment: